BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results

March 25, 2026 - 01:51

POMPANO BEACH, Fla., March 24, 2026 – BioStem Technologies, Inc., a leader in regenerative medicine, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company, which specializes in perinatal tissue allograft products, reported robust financial metrics for the period.

A key highlight from the report was the generation of $10.1 million in net revenue during the fourth quarter of 2025. The company achieved an exceptionally high gross margin of 97% for that quarter, underscoring the strength of its operational model and product portfolio.

Further solidifying its market position and growth trajectory, BioStem Technologies successfully completed a strategic acquisition. This move is anticipated to enhance the company's capabilities and expand its commercial reach within the regenerative medicine sector. The financial results reflect a period of significant execution and strategic advancement for the company as it continues to focus on developing and commercializing innovative biological solutions for wound care and tissue repair.